Advanced Affinity Maturation Service

Online Inquiry

Engineering Robust Biotherapeutics: Enhance Stability, Ensure Efficacy, and Accelerate Development

In the competitive landscape of therapeutic protein development, stability is not a feature—it is the foundation of a successful biologic. An unstable antibody can compromise safety, reduce efficacy, and lead to catastrophic failures in manufacturing and clinical trials. With over 20 years of dedicated expertise, Creative Biolabs offers an integrated, multi-platform approach to antibody stability improvement, transforming promising candidates into robust, commercially viable therapeutics.

Our services are engineered to de-risk your development pipeline, enhance product shelf-life, and ensure consistent performance from discovery to market. By combining advanced computational modeling, rational protein engineering, and high-throughput formulation screening, we address the root causes of instability to deliver antibodies with superior developability profiles.

Online Inquiry

The Critical Role of Antibody Stability in Therapeutic Success

Antibody stability is the measure of a protein's ability to maintain its native, functional conformation under various environmental stresses, including temperature fluctuations, pH shifts, mechanical stress, and long-term storage. A stable antibody is essential for:

Clinical Efficacy & Safety: Prevents aggregation, which is a leading cause of immunogenicity and can lead to adverse patient reactions. Ensures the antibody maintains its target-binding affinity and biological function.
Manufacturability & High Yields: Robust antibodies withstand the rigors of upstream and downstream processing, minimizing product loss and ensuring process consistency and high concentration formulation.
Extended Shelf-Life: Guarantees the therapeutic remains active and safe from the moment of manufacture to the point of administration, reducing waste and ensuring global supply chain viability.
Route of Administration: High stability is a prerequisite for developing high-concentration, low-viscosity formulations suitable for subcutaneous injection, a preferred route for patient convenience.

Fig. 1 Workflow for stability assessment and variant design of the VHH-Fc fusion antibody (HcAb).¹

Deconstructing Antibody Instability: Common Challenges We Solve

Antibody degradation is a complex process that can occur through multiple physical and chemical pathways. Our team possesses deep expertise in identifying and mitigating all forms of instability.

Physical Instability: This involves changes to the antibody's higher-order structure without altering its covalent bonds.

Chemical Instability: This involves the formation or breakage of covalent bonds, leading to irreversible modifications.

Our Integrated Antibody Stability Improvement Platform: A Multi-Pronged Strategy

Creative Biolabs rejects a one-size-fits-all approach. We have developed a synergistic, two-phase platform that systematically identifies and engineers out stability liabilities.

Phase 1: In Silico Developability Assessment & Stability Prediction

Before a single pipette is touched, our computational biology team leverages a suite of powerful AI/ML models and bioinformatics tools to perform a comprehensive in silico analysis.

Sequence-Based Hotspot Analysis: We screen antibody variable (V) region sequences for known instability motifs.
3D Structure & Aggregation Prediction: Using homology modeling, we generate 3D structures of the antibody's Fv region to identify surface-exposed hydrophobic patches and charge imbalances that are predictive of aggregation propensity (APR).

Phase 2: Rational Protein Engineering & Mutagenesis

Armed with in silico data, our protein engineering experts design and execute precise modifications to enhance stability without compromising function.

Targeted Mutagenesis: We perform site-directed mutagenesis to remove or mitigate instability hotspots. For example, replacing a labile asparagine with a more stable residue like glutamine or serine.
Hydrophobic Patch & Charge Engineering: We introduce targeted mutations to disrupt hydrophobic patches or optimize surface charge distribution, directly reducing the driving force for aggregation.
Framework & CDR Optimization: While preserving the core CDR residues essential for binding, we can optimize the surrounding framework or non-critical CDR residues to create a more stable structural scaffold.
Advanced Library Construction & Screening: For challenging antibodies, we can create rationally designed variant libraries and use high-throughput screening to select clones with the best combination of improved stability and retained affinity.

State-of-the-Art Analytical & Biophysical Characterization

Data is the cornerstone of our platform. We employ a comprehensive suite of cutting-edge analytical techniques to measure stability and guide our engineering efforts.

Analytical Technique	Stability Attribute Measured
Isothermal Titration Calorimetry (ITC)	Heat changes during molecular binding
Differential Scanning Calorimetry (DSC)	Thermal stability, melting temperature (Tm)
Dual-Polarization Interferometry (DPI)	Direct assessment of physical and structural stability in real-time
Differential Scanning Fluorimetry (DSF)	High-throughput thermal shift screening for formulation/mutants
Dynamic Light Scattering (DLS)	Aggregation onset temperature (Tagg), presence of aggregates
Size Exclusion Chromatography (SEC-MALS)	Precise quantification of monomers, dimers, and high MW aggregates
Capillary Electrophoresis (CE-SDS, cIEF)	Purity, charge heterogeneity, and chemical modifications
Mass Spectrometry (LC-MS)	Intact mass confirmation and identification of specific modifications
Intrinsic Fluorescence Spectroscopy	Conformational stability and tertiary structure integrity

Explore Our Specialized Stability Services

Our core platform supports a wide range of specialized applications. We invite you to explore our dedicated services for more information:

Antibody Humanization: Integrating stability assessment directly into the humanization process to ensure the final candidate is both non-immunogenic and robust.

Affinity Maturation: Ensuring that enhancements in binding affinity do not come at the cost of reduced stability.

Single Domain Antibody (SdAb) Stability Improvement Service: Fortifying sdAbs with intra-domain disulfides, CDR grafting, protease-resistant design, and client-tailored solutions.

Specificity Optimization Service: Engineering antibodies with fine-tuned specificity for closely homologous targets using advanced display libraries across any format.

Cysteine Modification Service: Adding free cysteines to antibodies without compromising function, rapidly delivering cost-efficient, high-quality tools for imaging, ADCs, and diagnostics.

Yeast Display based T Cell Receptor Engineering Service: Engineering T-cell receptors via combinatorial yeast surface-display library screening to accelerate clients' research worldwide.

Why Partner with Creative Biolabs?

20+ Years of Focused Experience

We have successfully optimized thousands of antibodies, from simple fragments to complex bispecifics and ADCs.

Integrated End-to-End Platform

Our seamless workflow from in silico design to final formulation saves you time and resources.

Scientific Partnership

We work as an extension of your team, providing transparent communication, expert consultation, and customized project designs.

The Engineering of Human IgG3 Antibody to Reduce Aggregation

Unwavering Commitment to Quality

Our robust analytical capabilities ensure you receive reliable, publication-quality data to support your regulatory filings.

Speed and Flexibility

Our high-throughput platforms and experienced project managers ensure rapid turnaround times to keep your project on track.

Take the next step in securing the future of your biologic therapeutic. Contact our experts today to discuss your project and learn how our antibody stability improvement services can enhance your path to the clinic.

Contact Us Today for a Free Quote!

Reference

Fang, Yuan, et al. "Enhancing the Protein Stability of an Anticancer VHH‐Fc Heavy Chain Antibody through Computational Modeling and Variant Design." Advanced Science (2025): 2500004. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1002/advs.202500004

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.